Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • suptavumab

    - PMLiVE

    Regeneron’s Libtayo receives EC approval for skin cancer

    Phase 3 trial results showed the drug significantly improved disease-free survival

    - PMLiVE

    Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition

    The deal includes an early-stage combination vaccine candidate for RSV and hMPV

    - PMLiVE

    Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid

    Around 27,000 adults in the US are living with uncontrolled cases of the chronic skin disease

    - PMLiVE

    Moderna’s RSV vaccine mRESVIA granted FDA approval to protect younger adults

    The vaccine is already approved in the US for use in adults aged 60 years and older

    - PMLiVE

    Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones

    These are the first clinical study results for the drug in a large population of patients with darker skin tones

    - PMLiVE

    Merck’s RSV monoclonal antibody Enflonsia approved by FDA to protect infants

    Enflonsia is now the first RSV preventive for infants that can be given at the same dose regardless of weight

    regeneron headquarters

    Regeneron’s bispecific antibody Lynozyfic approved by EC to treat multiple myeloma

    More than 35,000 new cases of the blood cancer are diagnosed in Europe every year

    - PMLiVE

    Sanofi/Regeneron’s Dupixent granted FDA approval for chronic spontaneous urticaria

    More than 300,000 people in the US are living with uncontrolled cases of the inflammatory skin disease

    - PMLiVE

    Pfizer’s RSV vaccine receives EC approval for individuals aged 18 to 59 years

    Abrysvo is now the first RSV vaccine in the EU for non-pregnant adults in this age group

    - PMLiVE

    Moderna’s RSV vaccine mRESVIA granted MHRA approval to protect older adults

    RSV is responsible for 14,000 hospitalisations per year in UK adults aged 65 years and older

    - PMLiVE

    Sanofi and Regeneron’s Dupixent granted FDA priority review for bullous pemphigoid

    Approximately 27,000 adults in the US are living with uncontrolled cases of the skin disease

    regeneron headquarters

    Regeneron shares positive late-stage results for poze-cemdi in rare blood disorder PNH

    Paroxysmal nocturnal haemoglobinuria affects up to 1.5 people per million in the US

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links